Hormone Refractory Prostate Cancer (HRPCA)Market Set To Touch $18.35 Billion By 2028

As per the report published by The Brainy Insights, global hormone refractory prostate cancer (HRPCA) market is expected to reach USD 18.35 billion by 2028, at a CAGR of 9.64% from 2021 to 2028. North America is accounting for the largest market value of USD 2.38 Billion in 2020, owing to the highly developed treatment scenarios in this region. The advancement in technologies, investment in R &D and the promising drugs in the pipeline are also the reason that North America region has the highest market value. Asia-Pacific is forecasted to have the highest CAGR of 9.84% during the forecast period. The biggest economies of the world India and China would be the most important region for this market. The increase in the education rate in the emerging economies are creating the awareness about the types of cancer and the types of treatment required for the treatment.

𝐆𝐫𝐚𝐛 𝐭𝐡𝐞 𝐬𝐚𝐦𝐩𝐥𝐞 𝐫𝐞𝐩𝐨𝐫𝐭- https://www.thebrainyinsights.com/enquiry/sample-request/12543
Hormone Refractory Prostate Cancer (HRPCA) Market Size by Treatment Type (Chemotherapy, Hormonal Therapy, Immunotherapy, Radiation Therapy, Surgery), End-User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics), Regions, Global Industry Analysis, Share, Growth, Trends, and Forecast 2021 to 2028

Key players operating in the global Hormone Refractory Prostate Cancer (HRPCA) market include AbbVie Inc., AcceleronPharma Inc., AB Science SA, AstraZeneca Plc., AstellasPharma Inc., Boston Biomedical Inc., Dendreon Corporation, Sanofi S.A, Johnson & Johnson and BioverativInc among others.The key players are now concentrating on implementing strategies such as adopting new technology, product innovations, mergers & acquisitions, joint venture, alliances and partnerships to improve their market position in the global Hormone Refractory Prostate Cancer (HRPCA) industry. For instance, in June 2018, Sanofi announced that it had completed the acquisition of Ablynx, a pharmaceutical company based in Ghent, Belgium, that develops therapeutic proteins based on single-domain antibody fragments. This acquisition would benefit Sanofi in obtaining a stronger foothold in the industry of medicine.

Treatment type segment include chemotherapy, hormonal therapy, immunotherapy, radiation therapy, surgery and others. The hormonal therapy segment is accounted for the largest market value of USD 4.12 Billion in 2020. The major consensus resorts to this treatment method because of the high amount of successful research in this technique.The end-user segment includes Hospitals, Ambulatory Surgical Centers, Specialty Clinics and Others. Hospitals had held the largest market share of 37.83% in the year 2020. This is because cancer treatments happens in hospitals and in Cancer specialized hospitals.

ACCESS FULL REPORT: https://www.thebrainyinsights.com/report/hormone-refractory-prostate-cancer-hrpca-market-12543
The premium pricing, which is blocking or making people reluctant of the treatment compounded with the reimbursement policies, which is also very uncertain, is the main factor restraining the market. The prostate cancer mostly affects old age people. So the rising geriatric population in the developed economies could show rising cases of Hormone Refractory Prostate Cancer (HRPCA), which will fuel this market.

About The Brainy Insights:

The Brainy Insights is a market research company, aimed at providing actionable insights through data analytics to companies to improve their business acumen. We have a robust forecasting and estimation model to meet the clients' objectives of high-quality output within a short span of time. We provide both customized (clients' specific) and syndicate reports. Our repository of syndicate reports is diverse across all the categories and sub-categories across domains. Our customized solutions are tailored to meet the clients' requirement whether they are looking to expand or planning to launch a new product in the global market.

Contact Us

Avinash D Head of Business Development

Phone: +1-315-215-1633

Email: sales@thebrainyinsights.com

Web: www.thebrainyinsights.com

This release was published on openPR.